
E.coli can turn plastic into painkillers, chemists discover
Scientists have found a way to use the bacteria E.Coli to convert plastic waste into a popular painkiller, a study said Monday, though outside experts doubted the technique would make a dent in the fight against plastic pollution.
Article content
Paracetamol, which is one of the most commonly used drugs worldwide, is made from the derivatives of fossil fuels, often by Asia-based subcontractors using cheap, polluting methods that contribute to climate change.
Article content
The world is also facing an escalating crisis of plastic pollution, with countries set for another bruising round of negotiations in August in the hope of sealing an international treaty to reduce plastic waste.
Article content
Article content
The British team of researchers behind the new study sought to find a solution to the two problems by roping in a third — E.coli, which is normally known for making people sick when they eat contaminated food.
Article content
First the chemists used a molecule derived from PET plastic, which is used in bottles and many other plastic products the world over, to spark a chemical reaction in a strain of E.coli.
Article content
This created a molecule they called PABA, according to the Nature Chemistry study, which was partly funded by drug firm AstraZeneca.
Article content
By genetically modifying the bacteria, the chemists were able to transform their molecule into acetaminophen, also known as paracetamol.
Article content
Article content
'This work demonstrates that PET plastic isn't just waste or a material destined to become more plastic — it can be transformed by microorganisms into valuable new products, including those with potential for treating disease,' lead study Stephen Wallace said in a statement.
Article content
Article content
Singaporean researchers not involved in the study praised how it combined synthetic and biological chemistry.
Article content
But 'several practical considerations remain' to take this idea beyond the proof-of-concept stage, they wrote in a linked commentary in the journal Nature Chemistry.
Article content
The chemical reaction produces only a limited amount of PABA molecules, which 'may be insufficient for industrial applications', they wrote.
Article content
Melissa Valliant, communications director of the Beyond Plastics project of Bennington College in the United States, expressed scepticism.
Article content
'These discoveries never scale up to anything significant enough to tackle the massive plastic pollution problem.'
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
8 hours ago
- Globe and Mail
Crohn's Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Crohn's Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Crohn's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Crohn's Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn's Disease Market. Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD). Some of the key takeaways from the Crohn's Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Crohn's Disease treatment therapies with a considerable amount of success over the years. Crohn's Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn's Disease treatment Emerging Crohn's Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn's Disease market in the coming years. In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers. In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract. In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn's and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn's disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies. In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn's disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group. Crohn's Disease Overview Crohn's Disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, most commonly affecting the small intestine and the beginning of the colon. It can lead to symptoms such as abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause is unknown but is believed to involve an abnormal immune response, genetics, and environmental factors. Crohn's can affect any part of the gastrointestinal tract and may lead to complications like strictures, fistulas, or bowel obstruction. While there is no cure, treatments including medications, dietary changes, and sometimes surgery can help manage symptoms and inflammation. Emerging Crohn's Disease Drugs Under Different Phases of Clinical Development Include: MORF 057: Morphic Therapeutic OTL-104: Orchard Therapeutics TP-317: Thetis Pharmaceuticals AZD 7798: AstraZeneca IMU 856: Immunic CBP-307: Suzhou Connect Biopharmaceuticals PF-06651600: Pfizer Deucravacitinib: Bristol-Myers Squibb E6011: Eisai Inc Guselkumab: Janssen Pharmaceutical Mirikizumab: Eli Lilly and Company Filgotinib: Gilead Sciences RHB-104: RedHill Biopharma Ozanimod: Celgene Corporation Brazikumab: AstraZeneca Crohn's Disease Route of Administration Crohn's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Crohn's Disease Molecule Type Crohn's Disease Products have been categorized under various Molecule types, such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Crohn's Disease Pipeline Therapeutics Assessment Crohn's Disease Assessment by Product Type Crohn's Disease By Stage and Product Type Crohn's Disease Assessment by Route of Administration Crohn's Disease By Stage and Route of Administration Crohn's Disease Assessment by Molecule Type Crohn's Disease by Stage and Molecule Type DelveInsight's Crohn's Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Crohn's Disease product details are provided in the report. Download the Crohn's Disease pipeline report to learn more about the emerging Crohn's Disease therapies Some of the key companies in the Crohn's Disease Therapeutics Market include: Key companies developing therapies for Crohn's Disease are - Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others. Crohn's Disease Pipeline Analysis: The Crohn's Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Crohn's Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn's Disease Treatment. Crohn's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Crohn's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Crohn's Disease Pipeline Market Drivers High prevalence of Crohn's Disease, increase in Drug Development for Crohn's treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn's Disease Market. Crohn's Disease Pipeline Market Barriers However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn's Disease Market growth. Scope of Crohn's Disease Pipeline Drug Insight Coverage: Global Key Crohn's Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others Key Crohn's Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and Crohn's Disease emerging therapies Crohn's Disease Market Dynamics: Crohn's Disease market drivers and Crohn's Disease market barriers Table of Contents 1. Crohn's Disease Report Introduction 2. Crohn's Disease Executive Summary 3. Crohn's Disease Overview 4. Crohn's Disease- Analytical Perspective In-depth Commercial Assessment 5. Crohn's Disease Pipeline Therapeutics 6. Crohn's Disease Late Stage Products (Phase II/III) 7. Crohn's Disease Mid Stage Products (Phase II) 8. Crohn's Disease Early Stage Products (Phase I) 9. Crohn's Disease Preclinical Stage Products 10. Crohn's Disease Therapeutics Assessment 11. Crohn's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Crohn's Disease Key Companies 14. Crohn's Disease Key Products 15. Crohn's Disease Unmet Needs 16 . Crohn's Disease Market Drivers and Barriers 17. Crohn's Disease Future Perspectives and Conclusion 18. Crohn's Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


National Post
8 hours ago
- National Post
Global vaccination efforts stall, leaving millions of children vulnerable to preventable diseases
LONDON (AP) — Efforts to vaccinate children globally have stalled since 2010, leaving millions vulnerable to tetanus, polio, tuberculosis and other diseases that can be easily prevented. Article content Protection from measles in particular dropped in 100 countries between 2010 and 2019, unravelling decades of progress, including in rich countries that had previously eliminated the highly infectious disease, according to a new analysis of global vaccination trends published Tuesday in the journal Lancet. Article content Article content 'After clean water, vaccination is the most effective intervention for protecting the health of our children,' said Helen Bedford, a professor of children's health at University College London, who was not connected to the research. She warned there has been a small but worrying rise in the number of parents skipping vaccination for their children in recent years, for reasons including misinformation. Article content Article content In Britain, Bedford said that has resulted in the largest number of measles recorded since the 1990s and the deaths of nearly a dozen babies from whooping cough. Vaccination rates in the U.S. are also falling, and exemptions from vaccinations are at an all-time high. Article content After the World Health Organization established its routine immunization program in 1974, countries made significant efforts to protect children against preventable and sometimes fatal diseases; the program is credited with inoculating more than 4 billion children, saving the lives of 154 million worldwide. Article content Since the program began, the global coverage of children receiving three doses of the diphtheria-tetanus-whooping cough vaccine nearly doubled, from 40 per cent to 81 per cent. The percentage of kids getting the measles vaccine also jumped from 37 per cent to 83 per cent, with similar increases for polio and tuberculosis. Article content Article content But after the COVID-19 pandemic, coverage rates dropped, with an estimated 15.6 million children missing out on the diphtheria-tetanus-whooping cough vaccine and the measles vaccine. Nearly 16 million children failed to get vaccinated against polio and 9 million missed out on the TB vaccine, with the biggest impact in sub-Saharan Africa. The study was funded by the Bill & Melinda Gates Foundation and Gavi, The Vaccine Alliance.

National Post
19 hours ago
- National Post
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Article content Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause 1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world 4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO 1,3,4 Enrollment for Galderma's phase II studies of nemolizumab is planned to begin in H2 2025 Article content ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4 'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.' BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. Article content Article content The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. Article content The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. Article content CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. Article content The study is being conducted in the U.S. and more information about the study will be made available soon on the website. Article content Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Article content Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: Article content References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch. 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio ® U.S. Prescribing Information. Available online. Accessed June 2025 6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR. 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online. Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed June 2025 Article content Article content Article content Article content Article content Contacts Article content For further information: Article content Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Article content Richard Harbinson Corporate Communications Director +41 76 210 60 62 Article content Céline Buguet Franchises and R&D Communications Director +41 76 249 90 87 Article content Emil Ivanov Head of Strategy, Investor Relations, and ESG +41 21 642 78 12 Article content Article content Article content